{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ffc1fe6b303132625aa8d15/6949562c4c1c9c7f2b5d8872?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What are the key clinical considerations for asparaginase-based regimens in pediatric vs AYA patients with ALL? ","description":"<p>The ALL Hub was pleased to speak with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children's Hospital, Salt Lake City, US. We asked, What are the key clinical considerations for asparaginase-based regimens in pediatric vs adolescent/young adult (AYA) patients with acute lymphoblastic leukemia (ALL)? </p><p><br></p><p>This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.</p>","author_name":"Scientific Education Support"}